301 BINNEY STREET, CAMBRIDGE, MA
FDA Approves ISEMBYLD for Spinal Muscular Atrophy Treatment
Investor Presentation
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock Files Prospectus Supplement for ATM Program with Jefferies
Shareholder Vote Results from Scholar Rock Annual Meeting on June 4, 2026
Annual Report to Security Holders
Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Q2
Q1
FY 2025
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Correspondence
Submission Upload